ADPT
Adaptive Biotechnologies Corp
29.40$
-0.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 51.0% | 42.8% | 43.1% | 44.7% | 35.9% | 38.0% | 32.4% | 30.6% | 19.3% | 25.4% | 26.4% | 28.8% | 24.6% | |
| 49.0% | 57.2% | 56.9% | 55.3% | 64.1% | 62.0% | 67.6% | 69.4% | 80.7% | 74.6% | 73.6% | 71.2% | 75.4% | |
| 75.2% | 62.8% | 72.2% | 58.7% | 52.0% | 48.9% | 46.2% | 41.0% | 25.2% | 30.4% | 33.3% | 26.8% | 28.6% | |
| 52.9% | 45.3% | 46.8% | 41.4% | 37.2% | 38.0% | 33.2% | 30.2% | 19.1% | 27.3% | 29.6% | 29.6% | 25.9% | |
| 183.4% | 212.4% | 173.3% | 164.8% | 134.4% | 133.3% | 124.1% | 112.0% | 69.7% | 92.4% | 100.7% | 93.3% | 87.6% | |
| -134.4% | -155.2% | -116.5% | -109.6% | -70.3% | -71.3% | -56.4% | -42.5% | 10.9% | -17.8% | -27.1% | -22.0% | -12.2% | |
| 9.6% | 6.6% | 7.1% | 6.2% | 6.3% | 6.2% | 5.5% | 5.0% | 3.2% | 4.1% | 4.1% | 3.8% | 3.7% | |
| -132.7% | -151.7% | -113.5% | -107.1% | -69.1% | -71.0% | -56.9% | -43.5% | 10.2% | -18.9% | -28.3% | -55.8% | -20.8% | |
| -15.2% | -0.1% | 10.0% | -0.1% | – | – | – | – | – | – | – | – | – | |
| -132.7% | -151.7% | -113.5% | -107.0% | -69.1% | -71.0% | -56.9% | -43.5% | 10.2% | -18.9% | -28.3% | -55.6% | -20.7% | |
| -107.9% | -133.4% | -93.9% | -89.3% | -52.9% | -55.5% | -56.4% | -30.8% | 18.0% | -9.0% | -20.3% | -16.9% | -5.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.